ADHD Drug Safety Evaluation Could Start With Short Cardiac Function Studies

Members of FDA's Drug Safety & Risk Management Advisory Committee are proposing short-term studies of cardiac function as a feasible method to evaluate cardiovascular risks associated with attention deficit/hyperactivity disorder drugs